-
POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDYResults demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.10 Apr 2013 -
Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®Recognizes Benefit of Hexvix in Reducing Recurrence Rate and Improving Time to Recurrence of Bladder Cancer03 Apr 2013
-
Wall Street Journal Features Visonac Development11 Mar 2013
-
Results fourth quarter and full year 201228 Feb 2013
-
Presentation of Cevira® Phase 2b Results05 Dec 2012
-
PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDYRESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX05 Dec 2012
-
Results third quarter and first nine months 2012Oslo, Norway, 26 October 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the third quarter and the first nine months 2012, for the period ended 30 September 2012.26 Oct 2012
-
Presentation of the third quarter 2012 report23 Oct 2012
-
Photocure to Exit Allumera BusinessOslo, Norway, 1 October 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has made the strategic decision to exit its Allumera® cosmetic dermatology business in the US.01 Oct 2012
